The autoreactivity of B cells in hereditary angioedema due to C1 inhibitor deficiency

Clinical and Experimental Immunology

Volumn 167, Issue 3, 2012, Pages 422-428

  Kessel, A ^a   Peri, R ^a   Perricone, R ^b   Guarino, M D ^b   Vadasz, Z ^a   Novak, R ^a   Haj, T ^a   Kivity, S ^c   Toubi, E ^a  

^a BNAI ZION MEDICAL CENTER   (Israel)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Autoantibodies; B cells; Hereditary angioedema; TLR 9; Total phosphotyrosine

Indexed keywords

ANTINUCLEAR ANTIBODY; CARDIOLIPIN ANTIBODY; COMPLEMENT COMPONENT C1S INHIBITOR; NEUTROPHIL CYTOPLASMIC ANTIBODY; PHOSPHOTYROSINE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE ANTIBODY; RHEUMATOID FACTOR; THYROID ANTIBODY; TOLL LIKE RECEPTOR 9;

ADULT; AGED; ANGIONEUROTIC EDEMA; ANTIBODY DETECTION; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MEMORY CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN ISOLATION;

ADULT; AGED; AUTOANTIBODIES; AUTOIMMUNITY; B-LYMPHOCYTES; CASE-CONTROL STUDIES; COMPLEMENT C1 INACTIVATOR PROTEINS; FEMALE; HEREDITARY ANGIOEDEMA TYPES I AND II; HUMANS; IMMUNOLOGIC MEMORY; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 9; YOUNG ADULT;

EID: 84856399435     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2011.04527.x     Document Type: Article

References (33)

1. Zuraw BL. Hereditary angioedema. N Engl J Med 2008; 359:1027-36.
2. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angio-oedema. Lancet 1998; 351:1693-7.
3. Han ED, MacFarlane RC, Mulligan AN, Scafidi J, Davis AE III. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest 2002; 109:1057-63.
4. Khan S, Tarzi MD, Doré PC, Sewell WA, Longhurst HJ. Secondary systemic lupus erythematosus: an analysis of 4 cases of uncontrolled hereditary angioedema. Clin Immunol 2007; 123:14-17.
5. Youinou P, Dorval JC, Cledes J, Leroy JP, Miossec P, Masse R. A study of familial lupus erythematosus-like disease and hereditary angio-oedema treated with danazol. Br J Dermatol 1983; 108:717-22.
6. Farkas H, Gyeney L, Nemesánszky E etal. Coincidence of hereditary angioedema (HAE) with Crohn's disease. Immunol Invest 1999; 28:43-53.
7. Massa MC, Connolly SM. An association between C1 esterase inhibitor deficiency and lupus erythematosus: report of two cases and review of the literature. J Am Acad Dermatol 1982; 7:255-64.
8. Muhlemann MF, Macrae KD, Smith AM etal. Hereditary angioedema and thyroid autoimmunity. J Clin Pathol 1987; 40:518-23.
9. Duncan IJ, Tymms KE, Carney G. Rheumatoid arthritis and hereditary angioedema. J Rheumatol 1988; 15:700-2.
10. Hory B, Haultier JJ. Glomerulonephritis and hereditary angioedema: report of 2 cases. Clin Nephrol 1989; 31:259-63.
11. Brickman CM, Tsokos GC, Balow JE etal. Immunoregulatory disorders associated with hereditary angioedema: I. Clinical manifestations of autoimmune disease. J Allergy Clin Immunol 1986; 77:749-57.
12. Brickman CM, Tsokos GC, Chused TM etal. Immunoregulatory disorders associated with hereditary angioedema. II. Serologic and cellular abnormalities. J Allergy Clin Immunol 1986; 77:758-67.
13. Farkas H, Csuka D, Gács J etal. Lack of increased prevalence of immunoregulatory disorders in hereditary angioedema due to C1-inhibitor deficiency. Clin Immunol 2011; 141:58-66.
14. Papadimitraki ED, Choulaki C, Koutala E etal. Expansion of toll-like receptor 9- expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process. Arthritis Rheum 2006; 54:3601-11.
15. Christensen SR, Kashgarian M, Alexopoulou L, Flavell RA, Akira S, Shlomchik MJ. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J Exp Med 2005; 202:321-31.
16. Krieg AM, Yi AK, Matson S etal. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 374:546-9.
17. Hartmann G, Krieg AM. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol 2000; 164:944-53.
18. Tan EM, Feltkamp TE, Smolen JS etal. Range of antinuclear antibodies in 'healthy' individuals. Arthritis Rheum 1997; 40:1601-11.
19. Ghosh P, Dwivedi S, Naik S etal. Antinuclear antibodies by indirect immunofluorescence: optimum screening dilution for diagnosis of systemic lupus erythematosus. Indian J Med Res 2007; 126:34-8.
20. Marin GG, Cardiel MH, Cornejo H, Viveros ME. Prevalence of antinuclear antibodies in 3 groups of healthy individuals: blood donors, hospital personnel, and relatives of patients with autoimmune diseases. J Clin Rheumatol 2009; 15:325-9.
21. Hayakawa K, Asano M, Shinton SA etal. Positive selection of natural autoreactive B cells. Science 1999; 285:13-16.
22. Talal N, Dauphinee M, Ahmed SA. CD5 B cells in autoimmunity. Ann NY Acad Sci 1992; 651:551-6.
23. Pers JO, Jamin C, Predine-Hug F, Lydyard P, Youinou P. The role of CD5-expressing B cells in health and disease [review]. Int J Mol Med 1999; 3:239-45.
24. Walport MJ, Davies KA, Morley BJ, Botto M. Complement deficiency and autoimmunity. Ann NY Acad Sci 1997; 815:267-81.
25. Pickering MC, Botto M, Taylor PR, Lachmann PJ, Walport MJ. Systemic lupus erythematosus, complement deficiency and apoptosis. Adv Immunol 2000; 76:227-324.
26. Mevorach D, Zhou JL, Song X, Elkon KB. Systemic exposure to irradiated apoptotic cells induces autoantibody production. J Exp Med 1998; 188:387-92.
27. Taylor PR, Carugati A, Fadok VA etal. A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo. J Exp Med 2000; 192:359-66.
28. Walport MJ, Davies KA, Botto M. C1q and systemic lupus erythematosus. Immunobiology 1998; 199:265-85.
29. Tedder TF, Inaoki M, Sato S. The CD19-CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity. Immunity 1997; 6:107-18.
30. Mongini PK, Vilensky MA, Highet PF, Inman JK. The affinity threshold for human B cell activation via the antigen receptor complex is reduced upon co-ligation of the antigen receptor with CD21 (CR2). J Immunol 1997; 159:3782-91.
31. Lyubchenko T, dal Porto J, Cambier JC, Holers VM. Coligation of the B cell receptor with complement receptor type 2 (CR2/CD21) using its natural ligand C3dg: activation without engagement of an inhibitory signaling pathway. J Immunol 2005; 174:3264-72.
32. Barrington RA, Zhang M, Zhong X etal. CD21/CD19 coreceptor signaling promotes B cell survival during primary immune responses. J Immunol 2005; 175:2859-67.
33. Fabiani JE, Paulin P, Simkin G, Leoni J, Palombarani S, Squiquera L. Hereditary angioedema: therapeutic effect of danazol on C4 and C1 esterase inhibitors. Ann Allergy 1990; 64:388-92.